These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 30821083)
1. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Ono T; Igawa S; Ozawa T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Katagiri M; Naoki K Thorac Cancer; 2019 Apr; 10(4):880-889. PubMed ID: 30821083 [TBL] [Abstract][Full Text] [Related]
2. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281 [TBL] [Abstract][Full Text] [Related]
3. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
4. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
5. Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment. Tanaka S; Tamiya M; Nishiuma S; Nakamura S; Nozaki K; Watanabe N; Itoh C; Kadokawa Y; Takeda K; Takahashi K; Miyazaki A; Kawamura T; Kunimasa K; Inoue T; Nishino K; Takagi M Cancer Treat Res Commun; 2024; 40():100836. PubMed ID: 39098310 [TBL] [Abstract][Full Text] [Related]
6. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
7. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
8. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559 [TBL] [Abstract][Full Text] [Related]
9. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450 [TBL] [Abstract][Full Text] [Related]
10. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012 [TBL] [Abstract][Full Text] [Related]
11. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM). Park S; Baldry R; Jung HA; Sun JM; Lee SH; Ahn JS; Kim YJ; Lee Y; Kim DW; Kim SW; Lee KH; Lee WJ; Choi JW; Chong K; Lee JI; Gwon SH; Son NH; Ahn MJ J Clin Oncol; 2024 Aug; 42(23):2747-2756. PubMed ID: 38828959 [TBL] [Abstract][Full Text] [Related]
12. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210 [TBL] [Abstract][Full Text] [Related]
13. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T; Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616 [TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709 [TBL] [Abstract][Full Text] [Related]
15. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
16. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Ahn MJ; Tsai CM; Shepherd FA; Bazhenova L; Sequist LV; Hida T; Yang JCH; Ramalingam SS; Mitsudomi T; Jänne PA; Mann H; Cantarini M; Goss G Cancer; 2019 Mar; 125(6):892-901. PubMed ID: 30512189 [TBL] [Abstract][Full Text] [Related]
17. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652 [TBL] [Abstract][Full Text] [Related]
18. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426 [TBL] [Abstract][Full Text] [Related]
19. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198 [TBL] [Abstract][Full Text] [Related]
20. Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. Makimoto G; Ohashi K; Senoo S; Hotta K; Maeda Y; Kiura K Intern Med; 2019 Jun; 58(11):1625-1627. PubMed ID: 30713295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]